 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
| Formerly | Brisbane Diamantina Health Partners |
|---|---|
| Industry | Healthcare |
| Founded | 2014 |
| Headquarters | Queensland, Australia |
| Website | https://healthtranslationqld.org.au/ |
Health Translation Queensland (formerly Brisbane Diamantina Health Partners (BDHP)) is the first Advanced Health Research Translation Centre in Queensland, Australia. [1]
Health Translation Queensland's history dates back to 2011, with the establishment of the Mayne Health Science Alliance and Diamantina Health Partners. In 2014, these two bodies came together with Children's Health Queensland in a collaborative arrangement to form the Brisbane Diamantina Health Partners Academic Health Science System. [1] [2] [3] [4]
The founding partners were Metro North Hospital and Health Service, Metro South Hospital and Health Service, Children’s Health Queensland Hospital and Health Service, Mater Health Services, The University of Queensland, Queensland University of Technology, the Translational Research Institute and the QIMR Berghofer Medical Research Institute. [5]
On 9 June 2017, it was announced Brisbane Diamantina Health Partners had been accredited by the National Health and Medical Research Council as a new Advanced Health Research and Translation Centre. [6]
BDHP changed its name to Health Translation Queensland in November 2021. [7]
The organisation is a collaboration between four hospitals, two universities, two medical research institutes, a primary health care network, and Queensland Health. [8]
The participants are:
The BDHP Brisbane Cancer Conference is held annually in December at the Brisbane Convention & Exhibition Centre. [9] The conference is convened by Professor Ken O’Byrne, Clinical Director of the Cancer and Ageing Research Program. [10] [11]
The BDHP Blood Cancers Group Seminar Series is held once a month, alternating between the Translational Research Institute on the Princess Alexandra Hospital campus and the QIMR Berghofer Medical Research Institute on the Royal Brisbane and Women's Hospital campus. Presentations are given by local, national and international researchers, providing an opportunity to hear about the latest research and encourage greater collaboration within and between research streams. [12] The series is convened by Professor Andrew Perkins, co-leader of the Blood and Bone Diseases Program, Mater Research Institute – University of Queensland.[ citation needed ]
The BDHP Circulating Tumour Cell Symposium was a single day event that provided up to date coverage of many aspects of tumour research. The event was co-convened by Professor Colleen Nelson, Executive Director of the Australian Prostate Cancer Research Centre-Queensland, and Professor Rik Thompson, of Queensland University of Technology's Institute of Health and Biomedical Innovation. The symposium was attended by some 130 delegates from Queensland University of Technology, The University of Queensland and Griffith Universities, affiliated research institutes, QLD Health, industry and consumer advocacy group representatives, as well as attendees from Victoria, New South Wales, Western Australia and South Australia. [13]
The University of Queensland is a public research university located primarily in Brisbane, the capital city of the Australian state of Queensland. Founded in 1909 by the Queensland parliament, UQ is one of the six sandstone universities, an informal designation of the oldest university in each state. UQ is also a founding member of edX, Australia's leading Group of Eight and the international research-intensive Association of Pacific Rim Universities.
The Princess Alexandra Hospital (PAH) is a major Australian teaching hospital of the University of Queensland, located in Brisbane, Queensland. It is a tertiary level teaching hospital with all major medical and surgical specialities onsite except for obstetrics, gynaecology, paediatrics, and medical genetics. It has a catchment population of 1.6 million people with 1038 beds and 5,800 full-time equivalent staff. In 2005, the hospital received Magnet Recognition.
The QIMR Berghofer Medical Research Institute is an Australian medical research institute located in Herston, Brisbane, in the state of Queensland. QIMR was established in 1945 by the Government of Queensland through the enactment of the Queensland Institute of Medical Research Act 1945 (Qld). Previously known as the Queensland Institute of Medical Research (QIMR), the original purpose of the institute was to further the study of tropical diseases in North Queensland. The current director is Professor Fabienne Mackay. The institute is a registered charity. In 2021, the institute was named as one of the Queensland Greats by the Queensland Government.
Michael F. Good was the Director of the Queensland Institute of Medical Research, from 2000 to 2010. He was Chair of the National Health and Medical Research Council.
The Institute of Health and Biomedical Innovation (IHBI) was an Australian collaborative medical research institute established in 2000 and based at the Queensland University of Technology (QUT) in Brisbane, Queensland. While the bulk of the institute was located at a purpose-built facility on the Kelvin Grove campus of QUT, a number of projects were conducted at sites across the two main QUT campuses and at multi-partner research institutes adjoining major hospitals. Research was also conducted at IHBI's Medical Engineering Research Facility (MERF), in the grounds of the Prince Charles Hospital.
The Prince Charles Hospital (TPCH) is a major teaching and tertiary referral hospital in the northern suburb of Chermside in Brisbane, Queensland, Australia. TPCH is a public hospital operated by Metro North Health, the largest public health service in Queensland Health and in Australia. The hospital is described to be the "leading cardiothoracic hospital in Australia", and is the hub for specialised services including heart and lung transplants, adult cystic fibrosis, adult congenital heart disease and complex cardiac care. The Nujum Jawa Crisis Stabilisation Unit opened in September 2024 is running adjacent to the Emergency Department, will provide 24/7 crisis support as well as targeted care.
Nicholas Gordon Martin is an Australian behavior geneticist who has published over 1300 peer-reviewed articles on topics including the heritability of religion and intelligence and medical disorders such as endometriosis. Martin is among the most cited medical scientists in the Southern Hemisphere, with a number of citation classics including "Genes, culture and personality: An empirical approach" that he co-authored with Lindon Eaves and Hans Eysenck, "Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus" (Nature, and "Genetic and environmental contributions to alcohol dependence risk in a national twin sample".
Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.
Pamela J. Russell was an Australian academic researcher of immunology, bladder and prostate research. Russell was awarded Membership of the Order of Australia (AM) for her research on prostate and bladder cancer in 2003.
Colleen Nelson is an Australian scientist specialising in prostate cancer research. She founded and directs the Australian Prostate Cancer Research Centre – Queensland (APCRC-Q). The Centre, based at the Translational Research Institute and the Princess Alexandra Hospital, spans the spectrum of discovery of new therapeutic targets and their preclinical and clinical development. She is also Chair of Prostate Cancer Research at Queensland University of Technology (QUT).
Georgia Chenevix-Trench is an Australian cancer researcher who investigates genetic predispositions to cancer.
Judith Ann Clements is an Australian academic and educator, specializing in Kallikrein proteases in prostate and ovarian cancers. Clements is the scientific director at the Australian Prostate Cancer Research Centre – Queensland and was head of the Cancer Research Program at the Institute of Health and Biomedical Innovation (IHBI) of Queensland University of Technology at the Translational Research Institute (Australia) from 1997 to 2014. Her biography was published in the Cancer and Metastasis Reviews in 2019
The Translational Research Institute (TRI) is Australia's first translational medical research institute dedicated to translating scientific discoveries into applications for medical practice.
Hudson Institute of Medical Research is a leading Australian medical research institute recognised internationally for discovery science and translational research.
Frank Gannon is a molecular biologist, and was the seventh Director of QIMR Berghofer Medical Research Institute in Brisbane, Australia. He has held high-profile appointments in scientific management and research in Ireland, England, the United States, France, Germany and Australia.
David Wayne Johnson is an Australian nephrologist known for kidney treatments and transplants in Australia. In 2009 he was a Queensland State Finalist for Australian of the Year, for his work in the early recognition and care of people with chronic kidney disease and specifically for his work in detection of chronic kidney disease.
Adele Chandler Green is an Australian epidemiological senior scientist at the QIMR Berghofer Medical Research Institute in Brisbane and is the institute's Head of Cancer and Population Studies Group.
Anne Kelso is an Australian biomedical researcher specialising in immunology and influenza. She is the Chief Executive Officer of the Australian Government's National Health and Medical Research Council (NHMRC).
Sarah Elizabeth Medland is Professor and Psychiatric Genetics Group Leader at the QIMR Berghofer Medical Research Institute in Herston, Brisbane, Australia. She played a major role in the development of the ENIGMA brain imaging consortium.
Fabienne Mackay is a French Australian research immunologist and institutional leader within the Australian medical research, education and innovation sectors. She is the Director and CEO of the QIMR Berghofer Medical Research Institute since 2020, after being the inaugural Head of the School of Biomedical Sciences at the University of Melbourne during the preceding five years. She is also an Honorary Professor at the Faculties of Medicine of the University of Queensland and the University of Melbourne. Her work has attracted public attention for its contribution to the pathophysiological understanding and treatment of lupus and other autoimmune diseases. Mackay has been notably awarded, achieving international reputation for her widely cited research describing B-cell activating factor (BAFF) and other cytokines of the TNF receptor superfamily, and their roles in B cell physiology, autoimmunity and cancer. She is an elected Fellow of the Australian Academy of Health and Medical Sciences.
